Disparities in the use of immunomodulators and biologics for the treatment of inflammatory bowel disease: A retrospective cohort study

被引:50
作者
Flasar, Mark H. [1 ]
Johnson, Tamara [2 ]
Roghmonn, Mary-Claire [1 ,2 ]
Cross, Raymond K. [1 ]
机构
[1] Univ Maryland, Sch Med, Maryland Hlth Care Syst, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA
关键词
race; inflammatory bowel disease; ulcerative colitis; Crohn's disease; therapy;
D O I
10.1002/ibd.20298
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Treatment disparities between African Americans (AA) and Caucasians exist in multiple diseases. There are limited studies in inflammatory bowel disease (IBD). Our objectives were to assess differences in 1131) therapies between AA and Caucasians, controlling for disease severity. Methods: We identified outpatients with ulcerative colitis (UC) or Crohn's disease (CD) evaluated at the University of Maryland and the Baltimore Veterans Affairs Medical Center from 1997-2005. We assessed medications used and the presence of covariates by race. Results: We identified 406 patients; 102 were AA (25%). AA were less likely to receive steroids (56% versus 68%; P = 0.02), mercaptopurine/azathioprine (6-MP/AZA) (28% versus 40%; P = 0.03), infliximab (IFX) (10% versus 20%; P = 0.03), or either 6-MP/AZA or IFX (28% versus 44%; P = 0.005). Age at diagnosis < 40 (odds ratio [OR] 2.22, 95% confidence interval [CI] 1.06-4.54), steroid use (OR 4.75, 95% Cl 1.93-11.7), and CD (OR 6.25, 95% CI 3.22-12.5) were positively associated with IFX use, while AA (OR 0.50, 95% CI 0.23-1.08) was negatively associated with IFX use. Age at diagnosis < 40 (OR 1.84, 95% CI 1.12-3.23), steroid use (OR 10.2,95% CI 5.37-19.2), and CD (OR 2.32,95% CI 1.43-3.20) were positively associated with either 6-MP/AZA or IFX use, while AA (OR 0.57, 95% CI 0.32-1.01) was negatively associated with 6-MP/AZA or IFX use. Conclusions: There were trends toward lower odds of treatment with IFX or either 6-MP/AZA or IFX in AA when compared with Caucasians. Further studies are needed to determine if these differences are due to less severe disease in AA patients or due to disparities in care.
引用
收藏
页码:13 / 19
页数:7
相关论文
共 34 条
[11]  
HIATT RA, 1988, WESTERN J MED, V149, P541
[12]   CROHNS-DISEASE AMONG ETHNIC-GROUPS IN A LARGE HEALTH MAINTENANCE ORGANIZATION [J].
KURATA, JH ;
KANTORFISH, S ;
FRANKL, H ;
GODBY, P ;
VADHEIM, CM .
GASTROENTEROLOGY, 1992, 102 (06) :1940-1948
[13]   CLASSIFICATION OF INFLAMMATORY BOWEL-DISEASE [J].
LENNARDJONES, JE .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1989, 24 :2-6
[14]   American Gastroenterological Association institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease [J].
Lichtenstein, GR ;
Abreu, MT ;
Cohen, R ;
Tremaine, W .
GASTROENTEROLOGY, 2006, 130 (03) :940-987
[15]   Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival [J].
Loftus, EV ;
Silverstein, MD ;
Sandborn, WJ ;
Tremaine, WJ ;
Harmsen, WS ;
Zinsmeister, AR .
GUT, 2000, 46 (03) :336-343
[16]   Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences [J].
Loftus, EV .
GASTROENTEROLOGY, 2004, 126 (06) :1504-1517
[17]   Racial disparities in the use of second-generation antipsychotics for the treatment of schizophrenia [J].
Mallinger, JB ;
Fisher, SG ;
Brown, T ;
Lamberti, JS .
PSYCHIATRIC SERVICES, 2006, 57 (01) :133-136
[18]   INFLAMMATORY BOWEL-DISEASE IN RURAL SUB-SAHARAN AFRICA - RARITY OF DIAGNOSIS IN PATIENTS ATTENDING MISSION HOSPITALS [J].
MAYBERRY, J ;
MANN, R .
DIGESTION, 1989, 44 (03) :172-176
[19]  
MENDELOF.AI, 1966, GASTROENTEROLOGY, V51, P748
[20]   FREQUENCY OF GLUCOCORTICOID RESISTANCE AND DEPENDENCY IN CROHNS-DISEASE [J].
MUNKHOLM, P ;
LANGHOLZ, E ;
DAVIDSEN, M ;
BINDER, V .
GUT, 1994, 35 (03) :360-362